Loading the records…
Loading the records…
The Accelerating Access to Critical Therapies for ALS Reauthorization Act extends an existing grant program through FY2031 but does not increase authorized funding levels. Early-stage bill with companion House language advancing gives moderate momentum. Direct market impact is low — ALS is a narrow disease area and the authorization extension does not change funding amounts.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The reauthorization is a non-event for large-cap healthcare equities. ALS is a niche indication with limited public company exposure. The bill's passage would provide modest regulatory certainty for early-stage ALS developers but does not change the competitive landscape for major neurology players. Investors should not expect any measurable stock price movement in large-cap pharma from this bill's progress.
S. 4472 was introduced on April 30, 2026, by Sen. Murkowski (R-AK) with Sen. Coons (D-DE) as cosponsor, and referred to the HELP Committee. It reauthorizes the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79) through fiscal year 2031. The companion bill, H.R. 8205, has been ordered to be reported (amended) by a 46-0 vote in the House, indicating broad bipartisan support. The bill is in early Senate committee stage.
This is an authorization bill — it extends the existing grant program for ALS research but does not appropriate new funds. The original ACT for ALS authorized competitive grants for research on therapies for ALS and other rare neurodegenerative diseases, but exact funding levels are set by subsequent appropriations. The bill also adds a clinical trial status review requirement where FDA will assess enrollment data and request interim trial data from manufacturers seeking grant renewals, and clarifies that phase 2/3 combined trials qualify under the program. A report on ALS and other rare neurodegenerative disease action plans is due within one year of enactment.
Structural winners are companies with active neuroscience/ALS pipelines. Lilly ($LLY) has broader neurology R&D including potential ALS candidates; AbbVie ($ABBV) has a neuroscience portfolio (including through Allergan legacy assets). However, any grant funding from this program is historically small (estimated <$50M annually) relative to these companies' revenue bases ($34.1B and $54.3B respectively). No publicly traded pure-play ALS companies are active; most ALS biotech is private or small-cap with limited liquidity.
No real market data for specific stock prices was provided. The bill is at early stage with no direct financial mechanism that would materially move large-cap pharma stocks. The companion House bill passing committee 46-0 signals strong bipartisan support, but the Senate path is uncertain.
Timeline: House committee has already reported H.R. 8205 (amended) by unanimous vote. Senate bill must clear HELP Committee, pass full Senate, then differences reconciled. Given the non-controversial nature and bipartisan sponsorship, passage in the 119th Congress is likely but not guaranteed. Enactment would likely occur before FY2026 end (September 30, 2026) given the original authorization expires in 2026.
Matched on shared policy language across AI analyses, with ticker & timing weight
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Accelerating Access to Critical Therapies for ALS Act
Justice for ALS Veterans Act of 2025
ALS Disability Insurance Access Act of 2019
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →